The Effect of Co-administration of Herbal extracts to Sorafenib (NexavarTM) on the QoL in patients with Hepatocellular carcinoma - pilot study
Not Applicable
- Conditions
- Not Applicable
- Registration Number
- KCT0001354
- Lead Sponsor
- Comprehensive and Integrative Medical Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
1.HCC patient who is taking Sorafenib or is planning to take Sorafenib.
2.ECOG performance 0~2
3.Age: 20 years ~ 80 years
4.No disability of cognitive function
5.Who voluntarily decide the participation of the study and sign the consent.
6.The patients who can be possible to follow up during the study periods.
Exclusion Criteria
1.HCC patient who is planning to surgery or other chemotherapy.
2.HCC patient who in needed surgical operation due to GI obstruction.
3.Hypertension whitch is not controlled antihypertensive drug.
4.Serum AST and ALT: above 150 U/mL, serum cratinine: above 3.4 mg/dL
5.Who can not sign the consent.
6.The patients who is inappropriated this study confirmed by researchers.
7.Women who have posive urine hCG.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QoL (EORCT QLQ-C30, QLQ-HCC18, KPS) and weight change;survival, adverse events of Sorafenib(diarrhea, weight loss, hand-foot skin reaction, skin eruption)
- Secondary Outcome Measures
Name Time Method Adverse events and overall safety